JP2008542270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542270A5 JP2008542270A5 JP2008513540A JP2008513540A JP2008542270A5 JP 2008542270 A5 JP2008542270 A5 JP 2008542270A5 JP 2008513540 A JP2008513540 A JP 2008513540A JP 2008513540 A JP2008513540 A JP 2008513540A JP 2008542270 A5 JP2008542270 A5 JP 2008542270A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- lipid
- construct
- alpha
- biotin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002632 lipids Chemical class 0.000 claims 101
- 108010047761 Interferon-alpha Proteins 0.000 claims 32
- 102000006992 Interferon-alpha Human genes 0.000 claims 32
- 102000014150 Interferons Human genes 0.000 claims 31
- 108010050904 Interferons Proteins 0.000 claims 31
- 229940079322 interferon Drugs 0.000 claims 31
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 25
- 239000004480 active ingredient Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 22
- 239000003443 antiviral agent Substances 0.000 claims 15
- 208000006454 hepatitis Diseases 0.000 claims 13
- 231100000283 hepatitis Toxicity 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 13
- 239000011616 biotin Substances 0.000 claims 11
- 235000020958 biotin Nutrition 0.000 claims 11
- 229960002685 biotin Drugs 0.000 claims 11
- 210000003494 hepatocyte Anatomy 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 8
- 108010005716 Interferon beta-1a Proteins 0.000 claims 8
- 108010005714 Interferon beta-1b Proteins 0.000 claims 8
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 8
- 229960004461 interferon beta-1a Drugs 0.000 claims 8
- 229960003161 interferon beta-1b Drugs 0.000 claims 8
- 230000007704 transition Effects 0.000 claims 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 7
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 claims 7
- 229910052804 chromium Inorganic materials 0.000 claims 7
- 239000011651 chromium Substances 0.000 claims 7
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 claims 5
- 239000000499 gel Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 108090000467 Interferon-beta Proteins 0.000 claims 4
- 102000003996 Interferon-beta Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 102000008070 Interferon-gamma Human genes 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 229960003130 interferon gamma Drugs 0.000 claims 4
- 229940095009 interferon gamma-1a Drugs 0.000 claims 4
- 229940028862 interferon gamma-1b Drugs 0.000 claims 4
- 108010042414 interferon gamma-1b Proteins 0.000 claims 4
- 229960001388 interferon-beta Drugs 0.000 claims 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- 206010019773 Hepatitis G Diseases 0.000 claims 3
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims 3
- 229940093541 dicetylphosphate Drugs 0.000 claims 3
- 208000005252 hepatitis A Diseases 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 108010051423 streptavidin-agarose Proteins 0.000 claims 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- ALIFRMFPRBTNNH-WFXMLNOXSA-N 12-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]dodecanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCCCCCCCC(=O)O)SC[C@@H]21 ALIFRMFPRBTNNH-WFXMLNOXSA-N 0.000 claims 2
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 2
- 239000011665 D-biotin Substances 0.000 claims 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- -1 acetyl triglycine Chemical compound 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 230000006837 decompression Effects 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 201000010284 hepatitis E Diseases 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- BPNHGUOHVHHZMG-WQYNNSOESA-N (3as,4s,6ar)-4-(4-aminobutyl)-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one;hydrochloride Chemical compound Cl.N1C(=O)N[C@@H]2[C@H](CCCCN)SC[C@@H]21 BPNHGUOHVHHZMG-WQYNNSOESA-N 0.000 claims 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- UXDBPOWEWOXJCE-DIPNUNPCSA-N 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine Chemical compound CCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCCCCCCCCCC UXDBPOWEWOXJCE-DIPNUNPCSA-N 0.000 claims 1
- BVKFQEAERCHBTG-UHFFFAOYSA-N 17,18,19-trihydroxypentatriacontane-16,20-dione Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCCCC BVKFQEAERCHBTG-UHFFFAOYSA-N 0.000 claims 1
- HKAVADYDPYUPRD-UHFFFAOYSA-N 1h-pyrazine-2-thione Chemical compound SC1=CN=CC=N1 HKAVADYDPYUPRD-UHFFFAOYSA-N 0.000 claims 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 claims 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 1
- CCSGGWGTGOLEHK-OBJOEFQTSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(5-aminopentyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCN)SC[C@@H]21 CCSGGWGTGOLEHK-OBJOEFQTSA-N 0.000 claims 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 claims 1
- XSXHTPJCSHZYFJ-MNXVOIDGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[(5s)-5-amino-6-hydrazinyl-6-oxohexyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(=O)NN)SC[C@@H]21 XSXHTPJCSHZYFJ-MNXVOIDGSA-N 0.000 claims 1
- NDKQUODALAUTFL-KWBADKCTSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-[(2-iodoacetyl)amino]ethyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCNC(=O)CI)SC[C@@H]21 NDKQUODALAUTFL-KWBADKCTSA-N 0.000 claims 1
- BRLRJZRHRJEWJY-VCOUNFBDSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[3-[3-(4-azido-2-nitroanilino)propyl-methylamino]propyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCN(C)CCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O BRLRJZRHRJEWJY-VCOUNFBDSA-N 0.000 claims 1
- DNXDWMHPTVQBIP-ZQIUZPCESA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[6-[(2-iodoacetyl)amino]hexyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCCNC(=O)CI)SC[C@@H]21 DNXDWMHPTVQBIP-ZQIUZPCESA-N 0.000 claims 1
- QLPHBNRMJLFRGO-YDHSSHFGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCCNC(=O)CCSSC1=CC=CC=N1 QLPHBNRMJLFRGO-YDHSSHFGSA-N 0.000 claims 1
- NTYQWCMGPMPMIR-GMMUSOBZSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;(2s,3s,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 NTYQWCMGPMPMIR-GMMUSOBZSA-N 0.000 claims 1
- YNIUDHSTAXEOHP-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;ethane-1,2-diamine Chemical compound NCCN.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YNIUDHSTAXEOHP-UFLZEWODSA-N 0.000 claims 1
- CIVGYTYIDWRBQU-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 CIVGYTYIDWRBQU-UFLZEWODSA-N 0.000 claims 1
- LOIYZIMLLRKKNS-FIKGOQFSSA-N Biotin-xx hydrazide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 LOIYZIMLLRKKNS-FIKGOQFSSA-N 0.000 claims 1
- 235000000638 D-biotin Nutrition 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 206010019771 Hepatitis F Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 150000001615 biotins Chemical class 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 150000003335 secondary amines Chemical class 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68387805P | 2005-05-23 | 2005-05-23 | |
| US11/384,575 US20070218117A1 (en) | 2006-03-20 | 2006-03-20 | Supra molecular construct for delivery of interferon to a mammal |
| PCT/US2006/019118 WO2006127360A2 (en) | 2005-05-23 | 2006-05-16 | Lipid construct for delivery of interferon to a mammal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008542270A JP2008542270A (ja) | 2008-11-27 |
| JP2008542270A5 true JP2008542270A5 (https=) | 2009-07-02 |
Family
ID=37452604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513540A Withdrawn JP2008542270A (ja) | 2005-05-23 | 2006-05-16 | インターフェロンを哺乳動物に送達するための脂質構築物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1883395A4 (https=) |
| JP (1) | JP2008542270A (https=) |
| KR (1) | KR20080042045A (https=) |
| AU (1) | AU2006249479A1 (https=) |
| CA (1) | CA2609376A1 (https=) |
| WO (1) | WO2006127360A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2563477T3 (es) * | 2007-08-03 | 2016-03-15 | Biotron Limited | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina |
| US8962015B2 (en) * | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| EP2235199A1 (en) * | 2007-12-17 | 2010-10-06 | Lux Innovate Limited | Compositions and methods for maintenance of fluid conducting and containment systems |
| US20150265679A1 (en) | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| CN111690539A (zh) * | 2020-07-07 | 2020-09-22 | 安徽农业大学 | 高效秸秆纤维素分解菌的筛选及应用 |
| IL303023A (en) * | 2020-11-27 | 2023-07-01 | D& D Pharmatech Inc | An oral formulation of a biologically active substance conjugate linked to a biotin unit, a fatty acid unit or a combination thereof |
| CN116916965A (zh) * | 2020-11-27 | 2023-10-20 | D&D制药技术股份有限公司 | 具有所偶联的生物素部分、脂肪酸部分或它们的组合的生物活性材料缀合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| GB9426484D0 (en) * | 1994-12-08 | 1995-03-08 | Ciba Geigy Ag | Compositions |
| TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
-
2006
- 2006-05-16 KR KR1020077029917A patent/KR20080042045A/ko not_active Withdrawn
- 2006-05-16 CA CA002609376A patent/CA2609376A1/en not_active Abandoned
- 2006-05-16 JP JP2008513540A patent/JP2008542270A/ja not_active Withdrawn
- 2006-05-16 WO PCT/US2006/019118 patent/WO2006127360A2/en not_active Ceased
- 2006-05-16 EP EP06770516A patent/EP1883395A4/en not_active Withdrawn
- 2006-05-16 AU AU2006249479A patent/AU2006249479A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548515T3 (es) | Complejos lipídicos recubiertos con PEG y su uso | |
| US7635463B2 (en) | Compositions for delivery of therapeutics and other materials | |
| Mével et al. | DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA | |
| Dutta et al. | Disulfide bridging strategies in viral and nonviral platforms for nucleic acid delivery | |
| AU2016297153B2 (en) | Compositions and methods for nanoparticle lyophile forms | |
| KR20110051214A (ko) | 약물 담체 | |
| JP2003520210A (ja) | 低い水溶性を有する薬物の送達のための薬学的処方物 | |
| HK1211205A1 (en) | Orally Bioavailable Lipid-based Constructs | |
| CN101094691A (zh) | 载体 | |
| CN106414749A (zh) | 用于胃肠给予rna的组合物 | |
| JP2001513544A (ja) | 脂質含有組成物及びこれらの使用 | |
| JP2000504579A (ja) | 高等真核細胞の形質移入のための組成物 | |
| JPWO2008010341A1 (ja) | 生理活性ポリペプチドまたはタンパク質内包高分子ポリマーミセルおよびその製造方法 | |
| JP2024514345A (ja) | オリゴヌクレオチドの経口送達 | |
| JP2008542270A5 (https=) | ||
| CN117545509A (zh) | 寡核苷酸的口服递送 | |
| JP2009542582A (ja) | 生物活性物質を細胞に送達するための物質および複合体 | |
| JP2025501905A (ja) | イオン化脂質、脂質ナノ粒子、及びこれらの使用 | |
| JP2009542582A5 (https=) | ||
| JP2024512770A (ja) | 遺伝子送達における非ウイルスベクターとしての樹状構造 | |
| Chen et al. | Thioamides adjacent to the ionizable amine headgroup in ionizable lipids reduce the pKa of lipid nanoparticles and enhance mRNA transfection efficiency in vitro and in vivo | |
| JP2001515060A (ja) | 新リポポリアミン、その調製および適用 | |
| JP2009507761A5 (https=) | ||
| JP2024505924A (ja) | 核酸送達 | |
| JP2008542270A (ja) | インターフェロンを哺乳動物に送達するための脂質構築物 |